DPP4 in Diabetes

Area of Science:

• Biochemistry
• Endocrinology
• Molecular Biology

Background:

• Dipeptidyl-peptidase 4 (DPP4) is a cell surface exopeptidase cleaving various substrates, including incretin hormones.
• DPP4 expression is dysregulated in diseases like diabetes, inflammation, cancer, and obesity.
• Incretin hormones (GLP-1, GIP) are key regulators of insulin secretion.

Purpose of the Study:

• To review current knowledge on the DPP4-incretin axis and DPP4 inhibitors.
• To evaluate recent findings on soluble DPP4 as an adipokine.
• To discuss the role of circulating DPP4 in cardiovascular disease and obesity.

Main Methods:

• Literature review of DPP4 function, incretin hormones, and DPP4 inhibitors.
• Analysis of studies on soluble DPP4, its receptor, and adipokine effects.
• Evaluation of data linking circulating DPP4 to obesity and vascular dysfunction.

Main Results:

• DPP4 inhibition by gliptins is a therapeutic strategy for type 2 diabetes.
• Soluble DPP4, identified as an adipokine, has paracrine and endocrine effects.
• Circulating DPP4 is elevated in obesity and type 2 diabetes, potentially linking these conditions to vascular dysfunction.

Conclusions:

• The DPP4-incretin axis is crucial for glucose homeostasis and diabetes management.
• Soluble DPP4's adipokine role highlights its involvement in cardiovascular disease pathogenesis.
• Circulating DPP4 may serve as a molecular link between obesity and vascular dysfunction, suggesting potential therapeutic targets.